Roche’s satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder
December 2, 2019Research and Development, Sales and Marketing Roche, pharma, satralizumab
Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), …
Top Ten most popular articles on Pharmafile.com this week
November 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boris Johnson, Jeremy Corbyn, NHS, Opiod, US, opiod crisis
The NHS was featured heavily in the news this week. Jeremy Corbyn revealed documents detailing previous UK-US discussions in which …
Few in NHS trust tech firms handling patient data
November 29, 2019Medical Communications AI, Boris, Corbyn, NHS, NHS Brexit, johnson
Few in the NHS trust ‘big tech’ companies to handle patient data in a confidential manner, a recent YouGov poll …
Immupharma and Avion sign agreement for lupus drug Lupuzor
November 29, 2019Medical Communications Diseases, Lupus, Lupuzor, avion
Immupharma has signed a development agreement with Avion Pharmaceuticals to acquire the licensing rights for Lupuzor, a peptide therapeutic and …
Study shows widespread bribery in Indian pharmaceutical industry
November 29, 2019Medical Communications India, Indian Pharma, Modi, bribery
A recent report by the Support for Advocacy and Training to Health Initiatives (Sathi) revealed the widespread use of bribes …
FDA gives priority review for AstraZeneca’s Imfinzi
November 29, 2019Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer
The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …
Prostate Cancer ‘super responders’ could live for two more years on Keytruda
November 28, 2019Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer
Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …
Majority of British people worried about the fate of the NHS in post-Brexit US trade deal, survey reveals
November 28, 2019Medical Communications Boris Johnson, Jeremy Corbyn, NHS, Trump, brexit, european union
In a newly released survey on “Over-The-Counter (OTC) and Pharma 2019”, by the business data platform Statista, 55% of people …
Drugmakers cut prices by 61% to get on Chinese reimbursement list
November 28, 2019Manufacturing and Production AstraZeneca, China, China National Reimbursement Scheme, Novartis, Roche Holding
AstraZeneca and Roche Holding are among a number of drugmakers to cut their prices in order to get on China’s …
Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
November 28, 2019Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma
Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …
US prosecutors open criminal probe of six drugs companies in opioid investigation
November 28, 2019Business Services, Manufacturing and Production Federal Substance Act, Opiod, Trump, Trump Opiod, opiod crisis
Federal Prosecutors from the US Attorney’s Office in the Eastern District of New York have subpoenaed five opioid manufactures. The …
Corbyn reveals documents showing US-UK meetings on deregulating NHS drug pricing
November 27, 2019Research and Development, Sales and Marketing Jeremy Corbyn, Labour Party, NHS, US, pharma
Labour Leader Jeremy Corbyn has showed off documents that detail secret trade meetings between the US and UK Governments, where …
Organisation of Islamic Cooperation sets up new halal pharmaceuticals technical committee
November 27, 2019Research and Development Arabic, Halal, Organisation of Islamic Cooperation, Saudi Arabia, malaysia
The Organisation of Islamic Cooperation’s (OIC) standards body, the Standards and Metrology Institute for Islamic Countries (SMIIC), has set up …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
NICE rejects Keytruda for routine use in NHS bladder cancer treatment
November 27, 2019Research and Development Cancer Drugs Fund, bladder cancer, cancer research
The National Institute for Health and Care Excellence (NICE) has given an initial ‘no’ for Keytruda’s (pembrolizumab) use in treating …
AstraZeneca and Novoheart team up to develop human ‘heart-in-a-jar’
November 27, 2019Research and Development Heart in a Jar, Novoheart, heart disease
AstraZeneca and Novoheart are collaborating on developing a functioning miniature human heart model of heart failure, a first of its …
FDA approves GBT’s Oxbryta to treat sickle cell disease
November 26, 2019Manufacturing and Production FDA, FDA Trump, Oxbryta, Sickle cell, sickle cell disease
The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which …
Singapore and South Korea agree to cooperate on Good Manufacturing Practice
November 26, 2019Manufacturing and Production ASEAN, GMP, North Korea, ROK, Singapore, south korea
At a joint summit on Saturday, South Korea’s Ministry of Food and Drug Safety signed a memorandum of understanding (MOU) …
US lawmakers call for FDA office in Israel
November 26, 2019Manufacturing and Production FDA, Golan Heights, Israel FDA, Netanyahu, Trump, USA, congress, israel
A bipartisan group of 21 US members of Congress has called for the establishment of an FDA office in Israel, …
Europe approves first subcutaneous version of biosimilar infliximab
November 26, 2019Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma
The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
